Hypereosinophilic Syndrome Market Competitive Analysis and Forecast 2017-2025: GlaxoSmithKline Plc., Bristol-Myers Squibb Company
Hypereosinophilic syndrome (HES) is a myeloproliferative disorder, which is characterized by persistently increased eosinophil count in blood and is associated with damage to multiple organs.
View full press release